Clinical Trial Update: A Bioequivalence Study of Two Oral Formulations of Topotecan in Patients With Advanced Solid Tumors [Phase 1]

View source ↗

Summary

This document reports results from a Phase 1 bioequivalence study comparing two oral formulations of Topotecan in patients with advanced solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer
• Solid Tumors

Drugs mentioned

• Topotecan (topotecan)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Lung Cancer, Small Cell, Solid Tumor Cancer | Phase 1 | Status: COMPLETED